TLR8 and skin neoplasm: The TLR7/TLR8 activator Aldara or 5 % imiquimod, has been approved for skin cancers, including BCCs, and has been found beneficial in metastatic melanoma (Coati et al., 2016[26]; Navi and Huntley, 2004[141]).